×
Brain Injury Awareness Month, observed each March, serves as a valuable opportunity to highlight the importance of preventing traumatic brain injury (TBI) and to advocate for strategies that support and enhance the quality of life of individuals living with TBI and their families. Beyond the acute phase, TBI is increasingly recognized as a risk factor for long-term neurological impairment and neurodegenerative disease.
Accurate and timely assessment is critical for patient management. While neuroimaging such as CT remains the cornerstone of acute evaluation, growing clinical evidence supports the complementary role of blood-based biomarkers in improving triage and monitoring.
Recent clinical guidelines and consensus statements—including recommendations from the Brain Trauma Foundation (BTF) and discussions within the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and other expert groups—highlight the emerging role of circulating biomarkers in:
As interest in blood-based TBI diagnostics continues to grow, assay developers require robust and well-characterized raw materials to ensure reliable performance. Hytest’s neuroscience portfolio has been well examined and adopted by IVD industry.
Explore Hytest's neuroscience portfolio!
Copyright © Hytest Ltd.